Clerkenwell Health CEO Tom McDonald tells Proactive the privately-held UK-based psychedelic-specialist contract research organization has partnered with Danish synthetic biology drug developer Octarine Bio to help advance patient access to psychedelics.
McDonald says the synthetic biology drug development company produces psilocybin from sugar using fermentation. The two will partners to expedite its clinical development with biosynthetic psilocybin and expects to be able to fast-track steps leading to human clinical trials.
Investorsinvestinginvestor
0 Comments